On-Pathway Regimens Are Associated With Significant Cost Savings for Treatment of Solid Tumors
Findings from a cross-institutional study suggest that on-pathway regimens led to significant cost savings for patients with cancer, despite the rate of hospitalizations and immune-related adverse events being similar between on-pathway and off-pathway regimens.
Stereotactic Ablative Body Radiotherapy Yields Long-Term Disease Control in Lung Oligometastases Regardless of Fractionation Schedule
Single-fraction stereotactic ablative body radiotherapy generated overall survival outcomes comparable to those achieved with multifraction SABR in patients with lung oligometastases.
Surgery and Radiotherapy Generate Similar Long-Term PROs in OPSCC
Long-term assessments did not reveal differences in patient-reported outcomes between primary surgery or radiotherapy for patients with oropharyngeal squamous cell carcinoma.
Older Patients Experience Functional Recovery 3 Months After Major Surgery for CRC
Three months following a major colorectal cancer surgery, the majority of older patients achieved functional recovery.
FOLFOX Produces Varying Toxicity Profile vs Chemoradiation in Rectal Cancer
Lower rates of diarrhea and overall bowel dysfunction were reported with the use of neoadjuvant fluorouracil and oxaliplatin vs neoadjuvant pelvic chemoradiation with fluorouracil (5FCURT) in patients with locally advanced rectal cancer. However, lower rates of other toxicities were reported in patients treated with 5FCURT.
SONIA Trial Suggests Second-line Use May Be Optimal for CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
The second line may be the optimal setting for patients with HR-positive, HER2-negative advanced breast cancer to receive CDK4/6 inhibitors plus an aromatase inhibitor followed by fulvestrant.
ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL
Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.
PRO Outcomes With Dostarlimab/Chemo Similar to Chemo Alone in 3-Year Follow-Up of Patients With Endometrial Cancer
Dostarlimab maintained the health-related quality of life in patients with primary advanced or recurrent endometrial cancer.
HIMALAYA Safety Data Support STRIDE Regimen as A Global Treatment Option for uHCC
Patients with unresectable hepatocellular carcinoma experienced manageable and low-grade immune-related adverse events with single tremelimumab regular interval durvalumab.
Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLL
The combination of venetoclax and obinutuzumab with or without ibrutinib generated higher rates of undetectable minimal residual disease (MRD) and progression-free survival vs chemoimmunotherapy in fit patients with chronic lymphocytic leukemia.
Cabozantinib Plus Nivolumab and Ipilimumab Provides PFS Benefit in Advanced RCC
The addition of cabozantinib to nivolumab and ipilimumab led to improved progression-free survival vs nivolumab and ipilimumab alone in patients with treatment-naïve advanced renal cell carcinoma; however, the rate of grade 3/4 adverse effects with the triplet was 79%.
Elacestrant PROs Consistent With Standard of Care Endocrine Therapy in Patients With Metastatic Breast Cancer
Elacestrant maintained the quality of life for patients with metastatic breast cancer for at least 6 treatment cycles, according to patient reported outcomes.
Novel Methylation-Based Platform Shows Promise for Multicancer Early Detection
A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.
Exome Sequencing Is A Feasible Way to Execute CDCT1 Genetic Condition Screening
Whole-exome sequencing successfully identified genetic conditions in patients who may have been missed by clinical guidelines.
Carolina Frailty Index Score Shows Utility in Ovarian Cancer Setting
Women with ovarian cancer may be effectively assessed for frailty status via the Carolina Frailty Index Score.
Similar Total Scores Are Observed With GCLQ and LELSQ in Assessing Patients With Endometrial Cancer for Lymphedema
The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed moderate to substantial agreement across different cutoff points.
New Approvals Continue to Shift Treatment Landscape in Hematologic Malignancies
Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.
Avelumab Efficacy Holds-Up In A Real-World Analysis of Patients With Locally Advanced, Metastatic Urothelial Carcinoma
The efficacy profile for avelumab in patients with locally advanced or metastatic urothelial carcinoma was consistent in a real-world setting with what had been reported in the phase 3 JAVELIN Bladder 100 trial.
Frontline Pola-R-CHP, CAR T-Cell Second-line Therapies Are Not Cost-effective in DLBCL
An economic analysis showed that neither polatuzumab vedotin-piiq added to standard of care chemotherapy nor CD19-directed chimeric antigen receptor T-cell therapy is likely to be the most cost-effective for patients with diffuse large B-cell lymphoma.
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
The high concordance rate between gastric and breast cancer HER2 scoring algorithms suggest that either may be used in the metastatic colorectal cancer setting.
LEAP-002 HRQOL Analysis Shows Comparable Scores with Pembrolizumab/Lenvatinib Vs Lenvatinib/Placebo in HCC
In the first-line treatment of patients with advanced hepatocellular carcinoma, a combination of pembrolizumab plus lenvatinib yielded similar health-related quality of life scores as lenvatinib plus placebo, according to a HRQOL analysis of the phase 3 LEAP-002 study.
Adjuvant Pembrolizumab Improves QOL vs Ipilimumab or HDI in Resected Melanoma
Treatment with adjuvant pembrolizumab resulted in favorable quality-of-life outcomes vs high-dose interferon α 2b or ipilimumab in patients with resected melanoma at high risk for relapse.
Oxaliplatin Treatment Duration Potentially Linked With Incidence of Severe Neuropathy in Stage III Colon Cancer
Patients with stage III colon cancer who receive longer courses of adjuvant oxaliplatin, exercise for less than 9 hours per week, have diabetes, or have a higher body mass index could experience higher rates of severe oxaliplatin-induced peripheral neuropathy.
GRIFFIN Patient-Reported Outcomes Data Support Frontline Daratumumab-Quadruplet Therapy in Transplant Eligible, Newly Diagnosed, Multiple Myeloma
Daratumumab in addition to bortezomib, lenalidomide, and dexamethasone induction/consolidation therapy, as well as with lenalidomide maintenance, showcased a promising health-related quality of life benefit for patients with transplant eligible, newly diagnosed multiple myeloma.
Trastuzumab Deruxtecan, With or Without Endocrine Therapy, Shows Promising Responses in Operable HR+, HER2-Low Breast Cancer
Neoadjuvant treatment with trastuzumab deruxtecan showed promising responses in patients with early-stage breast cancer.
Extended Treatment Time With Bevacizumab Does Not Confer PFS Benefit in Ovarian Cancer
Increasing the duration of bevacizumab treatment in the frontline setting did not improve progression-free survival for patients with advanced ovarian cancer.
Forging a New Field
Almost single-handedly, Jennifer Temel, MD, defined a research field in medicine, creating a new focus on quality of life for patients and survivors.
Quality Improvement Project Shows Reduced Time From Diagnosis to NGS in Patients With NSCLC
The median time between pathologic diagnosis to next-generation sequencing was reduced in a quality improvement project for patients with newly diagnosed metastatic non–small cell lung cancer.
Emerging Therapies Prompt Nuanced AE Management in Kidney Cancer
Kiran Virdee, RN, BSN, CCRN-K, outlines the best practices for the management of adverse effects during the treatment of kidney cancer.
Encorafenib/Binimetinib Delivers Prolonged Survival in BRAF V600–Mutant Melanoma
The combination of encorafenib and binimetinib led to sustained improvements in progression-free survival and overall survival, without new safety signals in patients with BRAF V600–mutant melanoma, according to 5-year follow-up of the phase 3 COLUMBUS trial.
PVd Extends OS and PFS in Relapsed/Refractory Multiple Myeloma
At Multiple Dose Levels, Mezigdomide Elicits Responses in Combination With Bortezomib or Carfilzomib in R/R Myeloma
Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma
Systemic Review Sheds Light on Efficacy of Bispecific Antibodies in Extramedullary R/R Multiple Myeloma
2 Clarke Drive Cranbury, NJ 08512